CEACAM5 and colorectal carcinoma: Specifically, for early-stage CRC, the positive rate of CEA was 38.6%, which was less than that of autoantibodies against ALDH1B1 (62.7%), UQCRC1 (54.2%), CTAG1 (64.4%), and CENPF (62.7%) (Figure 4).